Skye Bioscience marks SBI-100 clinical trial progress with new clinical research organization

News Direct

Wed, Feb 8, 2023, 7:19 AM1 min read

In this article:

New York --News Direct-- Skye Bioscience Inc

Skye Bioscience CEO Punit Dhillon joined Proactive's Natalie Stoberman to share the latest progress on its SBI-100 Ophthalmic Emulsion (OE) clinical trials.

SBI-100 OE, the company's lead program, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness.

Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs.

Contact Details

Proactive Investors US

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/skye-bioscience-marks-sbi-100-clinical-trial-progress-with-new-clinical-research-organization-243499754

Suze Orman Decided To Drop Homeowners Insurance After An Outrageous Quote: '$28,000 For A 2,100-Square-Foot Condo. Are You Kidding Me?'
Finance expert Suze Orman has voiced concerns about the impact of climate change on property insurance costs, asserting it could threaten the American dream of homeownership. Orman, 72, faced a $28,000 annual insurance quote for her Florida oceanside condo, leading her to forego coverage entirely. She highlights a troubling trend where soaring insurance costs driven by frequent and severe weather events may deter Americans from buying homes. Don't Miss: For many first-time buyers, a house is abo
Benzinga•16h ago
Cathie Wood's Ark Empire Bleeds As Investor Outflows Spike: 'The Loyal Shareholders Have Become Frustrated'
In early 2021, Ark Invest, led by tech investor Cathie Wood, managed a staggering $59 billion across six funds, making it the world’s largest active ETF manager. Three years later, a significant 80% downturn occurred, with assets under management in those funds plummeting to just $11.1 billion. This decline can be attributed to a combination of factors, including high interest rates dampening Wood’s long-term speculative tech investments and the subsequent wave of outflows from disillusioned inv
Benzinga•14h ago
The IRS says it’s going after wealthy tax cheats. Here’s what new audit stats show.
After Congress approved billions of extra funding for tax compliance, the Internal Revenue Service pledged it would get tougher on rich taxpayers and corporations while avoiding extra scrutiny of middle-class households.
MarketWatch•19h ago
On a crucial earnings call, Musk reminds the world Tesla is a tech company. ‘Even if I’m kidnapped by aliens tomorrow, Tesla will solve autonomy’
After a dismal quarter for Tesla, CEO Elon Musk tried to reassure investors the company’s real value was its effort to perfect self-driving cars.
Fortune•8h ago
JPMorgan’s ‘Bloody Friday’: Why Several Top Financial Advisors Jumped Ship the Same Day
Six teams managing nearly $15 billion in total assets quit JPMorgan Chase’s brokerage unit to join competitors last Friday. Here’s what may have triggered their departures.
Barrons.com•14h ago
3 Super-Safe Stocks That Could Reach 70 Consecutive Years of Dividend Raises By 2032
When it comes to reliable passive income, these three dividend-paying companies are best in breed.
Motley Fool•23h ago
Oracle to Move Headquarters Again, This Time to Nashville
CEO Larry Ellison said the relocation will help the company better integrate with the healthcare industry.
The Wall Street Journal•9h ago
Forget Nvidia: Billionaires Are Selling It and Buying These 2 High-Octane Artificial Intelligence (AI) Growth Stocks Instead
Billionaire investors are ditching the "infrastructure backbone" of the artificial intelligence (AI) revolution in favor of two industry-leading, irreplaceable AI stocks.
Motley Fool•1d ago
Should You Buy Intel Stock Before Earnings?
Intel is underperforming the broader semiconductor index.
Motley Fool•14h ago
Time to Pounce: 2 Phenomenal Ultra-High-Yield REITs That Haven't Been This Cheap in Years
The premier name among retail REITs, along with a 14%-yielding REIT that's returned $25 billion to its shareholders since going public, make for sensational buys right now.
Motley Fool•1d ago

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Skye Bioscience marks SBI-100 clinical trial progress with new clinical research organization

Contact Details

Recommended Stories

Suze Orman Decided To Drop Homeowners Insurance After An Outrageous Quote: '$28,000 For A 2,100-Square-Foot Condo. Are You Kidding Me?'

Cathie Wood's Ark Empire Bleeds As Investor Outflows Spike: 'The Loyal Shareholders Have Become Frustrated'

The IRS says it’s going after wealthy tax cheats. Here’s what new audit stats show.

On a crucial earnings call, Musk reminds the world Tesla is a tech company. ‘Even if I’m kidnapped by aliens tomorrow, Tesla will solve autonomy’

JPMorgan’s ‘Bloody Friday’: Why Several Top Financial Advisors Jumped Ship the Same Day

3 Super-Safe Stocks That Could Reach 70 Consecutive Years of Dividend Raises By 2032

Oracle to Move Headquarters Again, This Time to Nashville

Forget Nvidia: Billionaires Are Selling It and Buying These 2 High-Octane Artificial Intelligence (AI) Growth Stocks Instead

Should You Buy Intel Stock Before Earnings?

Time to Pounce: 2 Phenomenal Ultra-High-Yield REITs That Haven't Been This Cheap in Years